MLSS

Business Context and Reporting Period

Milestone Scientific Inc. (MLSS) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company designs and commercializes computer-controlled injection technologies for dental (CompuDent, STA) and medical (CompuFlo, CathCheck) applications. It operates as a smaller reporting company with a significant accumulated deficit and relies on third-party manufacturers for its products.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: For the three months ended September 30, 2025, net sales decreased by 6% ($154k) compared to the prior year, driven by lower international and e-commerce dental sales. However, for the nine-month period, revenue increased by 5% ($300k), aided by a re-entry into the China market ($310k in sales vs. $0 in 2024) and growth in the medical segment.
• Expenses: Selling, General, and Administrative (SG&A) expenses decreased by 10% ($325k) in the quarter due to workforce optimization and reduced marketing/consulting fees. Research and Development (R&D) expenses dropped significantly by 93% ($216k) in the quarter as the company delayed development of the next-generation STA instrument to focus on commercialization.
• Profitability: The operating loss improved by 22% ($335k) in the quarter and by 2% ($98k) for the nine-month period, primarily due to the reduction in R&D and SG&A spending.
• Financing: The company issued $800,000 in convertible notes to related parties (directors) in April 2025, which were not present in the prior year.

Outlook, Risks, and Management Commentary

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. This is due to recurring losses, an accumulated deficit of $132.7 million, and a need for additional capital to finance operations.
• Strategy: The company is prioritizing commercial expansion of existing products (CompuFlo, CathCheck) and dental sales over new R&D. It is actively pursuing equity or debt financing to support its operating plan.
• Risks:
  • Liquidity: Cash burn from operations was $2.7 million for the nine months ended September 30, 2025. Failure to raise capital could force delays in commercialization.
  • Supply Chain: The company relies on informal arrangements with third-party manufacturers. Termination of these relationships could materially harm operations.
  • Regulatory/Trade: Potential changes in U.S. tariffs and trade policies, particularly regarding China (a source of essential elements), pose risks to costs and supply.
  • Concentration: Three distributors accounted for 56% of accounts receivable, and three suppliers accounted for 76% of accounts payable as of September 30, 2025.
• Unusual Items: In April 2024, the company recorded a $2.0 million gain from the sale of New Jersey net operating losses (NOLs). No such gain was recorded in the current period.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.3 million cash balance against the $2.7 million operating cash burn rate for the nine-month period.
• Financing Status: Confirm if the company has secured the additional equity or debt financing required to address the "substantial doubt" going concern warning.
• China Market Sustainability: Assess the durability of the new $310k revenue stream from China and potential exposure to trade tariffs.
• Related Party Transactions: Review the terms of the $800,000 convertible notes issued to directors and the potential for future dilution upon conversion.
• Inventory Valuation: Note the $1.1 million allowance for slow-moving medical finished goods and monitor for further write-downs.